The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
GLPG2737 on top of Orkambi in subjects with cystic fibrosis
Study DrugGLPG2737
Type of Study DrugCFTR modulator
Study TitleA Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation
Study Phase2a
Study SponsorGalapagos

Link on (link is external)

Participating ECFS-CTN sitesPlease contact for most recent sitelist
Age18 years and older